Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Replimune Group ( (REPL) ) has provided an update.
On September 3, 2025, Replimune Group held its annual stockholders’ meeting where key proposals were voted on, including the election of Class I directors and the ratification of PricewaterhouseCoopers LLP as the independent accounting firm. Notably, an amendment to the company’s 2018 Omnibus Incentive Compensation Plan was not approved. Additionally, the company announced a scheduled Type A meeting with the FDA to discuss their Biologics License Application for RP1 in combination with nivolumab for advanced melanoma. The outcome of this meeting is crucial as it could impact the continuation of the RP1 program, which is significant for stakeholders given the limited treatment options for melanoma.
The most recent analyst rating on (REPL) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Replimune Group stock, see the REPL Stock Forecast page.
Spark’s Take on REPL Stock
According to Spark, TipRanks’ AI Analyst, REPL is a Neutral.
Replimune Group’s stock score reflects its early-stage status in the biotechnology sector, characterized by significant R&D investments leading to negative earnings and cash flows. While the company shows strong equity, the current technical indicators suggest mixed to bearish market momentum. Valuation remains challenging due to negative earnings. The company’s future success hinges on the development and commercialization of its products.
To see Spark’s full report on REPL stock, click here.
More about Replimune Group
Replimune Group, Inc., headquartered in Woburn, MA, is a clinical stage biotechnology company focused on developing novel oncolytic immunotherapies. Their proprietary RPx platform is designed to enhance the immunogenicity of tumor cell death and activate a systemic anti-tumor immune response, making it versatile for use alone or in combination with other cancer treatments.
Average Trading Volume: 9,095,178
Technical Sentiment Signal: Sell
Current Market Cap: $460.5M
See more insights into REPL stock on TipRanks’ Stock Analysis page.